---
title: "Acrivon Therapeutics Q1 Loss Narrows"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286319832.md"
description: "Acrivon Therapeutics reported a Q1 loss of $0.49 per diluted share, an improvement from a loss of $0.51 a year ago. Analysts had expected a loss of $0.52. The biopharmaceutical company has sufficient funds to continue operations into Q3 of 2027."
datetime: "2026-05-13T21:14:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286319832.md)
  - [en](https://longbridge.com/en/news/286319832.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286319832.md)
---

# Acrivon Therapeutics Q1 Loss Narrows

05:14 PM EDT, 05/13/2026 (MT Newswires) -- Acrivon Therapeutics ( ACRV ) reported late Wednesday a Q1 loss of $0.49 per diluted share, against a loss of $0.51 a year ago.

Analysts polled by FactSet expected a loss of $0.52.

The clinical stage biopharmaceutical company said it has funds to operate into Q3 of 2027.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [ACRV.US](https://longbridge.com/en/quote/ACRV.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [3 Best Healthcare Stocks to Buy in May 2026, According to Analysts](https://longbridge.com/en/news/286619134.md)
- [Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | IMUX Stock News](https://longbridge.com/en/news/286894992.md)
- [Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst](https://longbridge.com/en/news/286597352.md)
- [Sanofi: Information concerning the total number of voting rights and shares - April 2026](https://longbridge.com/en/news/286946199.md)